Nyvepria (Pegfilgrastim)

Pegfilgrastim, the active ingredient in Nyvepria, is a colony-stimulating factor presented as a subcutaneous injection for oncology supportive care use. It reduces the duration of neutropenia in patients receiving myelosuppressive chemotherapy. GNH USA supplies Nyvepria as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Nyvepria as a licensed, GDP‑compliant international pharmaceutical supplier serving  hospitals  oncology  centres  pharmacies and  clinics worldwide.

Nyvepria is a granulocyte‑colonial‑stimulating factor that operates        ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​ ​  ​  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​  ​  ​ ​ ​ ​ ​​ ​ ​

- Breast cancer: helps maintain neutrophil counts during chemotherapy cycles. - Lung cancer: reduces risk of febrile neutropenia after myelosuppressive regimens. - Non‑Hodgkin lymphoma: supports bone‑marrow recovery following intensive chemotherapy.

Common Side Effects: - Bone‑doughnut     ... ... ...  ...  …  ... … … … ... … … … … … … … … … … … … … … … … ... ... … … … ... … … … … … … … …

Serious or Rare Side Effects: -  …  …  …  …  ...  …  …

Nyvepr2    

      t    t  d  \